Alpha Teknova (TKNO) Q2 Revenue Jumps 7%

Alpha Teknova (NASDAQ:TKNO), a specialist in custom bioprocess solutions for the life sciences sector, released its results on August 7, 2025. The most important news: Revenue (GAAP) rose by 7%, reaching $10.3 million, and net loss per share (GAAP) narrowed to $0.07, both of which (GAAP) surpassed market expectations. Analysts had forecast a $0.10 loss per share (GAAP) and $10.3 million in GAAP revenue. The quarter featured positive developments in margin expansion and operational efficiency, signaling ongoing improvement, although the company continued to report net losses. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Alpha Teknova (NASDAQ:TKNO) provides highly customized reagents and solutions for researchers and developers in the biotechnology, pharma, and diagnostics fields. The company manufactures products such as custom research-use-only media, buffers, and components used in key segments of life sciences including cell and gene therapies, mRNA vaccines, and molecular diagnostics.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool